Recent Updates
Recently added Catalysts
VKTX Neutral Sentiment

Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study

Tuesday, March 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the Phase 2 VENTURE study of VK2735, a dual agonist targeting GIP and GLP-1 receptors for weight management. The study is randomized and spans 13 weeks, focusing on the efficacy and safety of VK2735. Further details about the management and pipeline of the company are also provided.
Price reaction · baseline $33.61 (2026-03-09 close) · hit pre-market · 1 other VKTX headline(s) in the window, move may be shared
day 0 close · peak
+3.1%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
13.6%
average across 5 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
VK2735
Phase 3 · Weight Loss

Full Press Release Details

• About Management Board of Directors Careers
• Pipeline Overview VK2735 VK3019 VK2809 VK0214 VK5211 Publications
• Investors Overview Stock Information Stock Chart Historical Price Lookup News & Events Press Releases Webcasts SEC Filings Analyst Coverage Corporate Governance Governance Highlights Mangement Board of Directors Committee Composition Shareholder Services Information Request E-mail Alerts Investor Relations Contacts Corporate Presentation
• Contact
• Management
• Board of Directors
• Careers
• Overview
• VK2735
• VK3019
• VK2809
• VK0214
• VK5211
• Publications
• Overview
• Stock Information Stock Chart Historical Price Lookup
• News & Events Press Releases Webcasts
• SEC Filings
• Analyst Coverage
• Corporate Governance Governance Highlights Mangement Board of Directors Committee Composition
• Shareholder Services Information Request E-mail Alerts Investor Relations Contacts
• Corporate Presentation
• Stock Chart
• Historical Price Lookup
• Press Releases
• Webcasts
• Governance Highlights
• Mangement
• Board of Directors
• Committee Composition
• Information Request
• E-mail Alerts
• Investor Relations Contacts
ShareAdd on Google
Tags: VKTX Viatris Investor Conferences Healthcare VK2735 weight management GIP GLP-1
Last updated: Mar 10, 2026

Biotech snapshot

Cash runway
$502M liquidity · $42M/mo burn
~11 mo
Medium dilution risk
Lead asset
VK2735Phase 3
Weight Loss →

Catalyst track record

+53%
best trade around VKTX's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for VKTX.

See every catalyst's timing & PoA →